Oric Pharmaceuticals (ORIC) Non-Current Deferred Tax Liability (2022 - 2025)

Oric Pharmaceuticals' Non-Current Deferred Tax Liability history runs 4 years deep, the most recent figure standing at $220000.0 for Q4 2025.

• Quarterly Non-Current Deferred Tax Liability fell 91.5% year-over-year to $220000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $220000.0 (down 91.5% YoY) and the FY2025 annual result came in at $220000.0, down 91.5% from the prior year.
• Non-Current Deferred Tax Liability was $220000.0 for Q4 2025 at Oric Pharmaceuticals, down from $2.6 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $24.0 million in Q4 2023 and bottomed at $106000.0 in Q4 2022.
• A 4-year average of $6.7 million and a median of $1.4 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2023 — Non-Current Deferred Tax Liability surged 22567.92% — and 2025, when it plunged 91.5%.
• Oric Pharmaceuticals' Non-Current Deferred Tax Liability stood at $106000.0 in 2022, then jumped by 22567.92% to $24.0 million in 2023, then sank by 89.23% to $2.6 million in 2024, then plunged by 91.5% to $220000.0 in 2025.
• Business Quant data shows ORIC's Non-Current Deferred Tax Liability at $220000.0 in Q4 2025, $2.6 million in Q4 2024, and $24.0 million in Q4 2023.